$1,650.00
We use our efficient integration-free, small-molecule-based method to differentiate high-quality cardiomyocytes from human iPSCs. The differentiated cardiomyocytes recapitulate the phenotype and functional parameters of primary and in vivo cardiomyocytes.
We provide cardiomyocytes differentiated from an integration-free, control human iPSC line (ASE-9211), reprogrammed from fibroblasts of an African American male donor. These high-purity (>80%) cells express high levels of cTnT. The cryopreserved cardiomyocytes are ready to use in 2-3 days after recovery, and are functionally viable for 7-14 days after recovery.
These iPSC-differentiated cardiomyocytes can be used as control lines to compare phenotype and functionality of patient-derived, genome-edited iPSC-derived cardiomyocytes for drug screening applications.
| Table Header | Table Header |
|---|---|
|
Age |
Neonate |
|
Gender |
Male |
|
Ethnicity |
African American |
|
Tissue source |
Dermal fibroblasts |
|
Reprogramming method |
Episomal |
|
Culture conditions |
Feeder-free |
